Total Payments
$269,017
2024 Payments
$7,206
Companies
21
Transactions
285
Medicare Patients
552
Medicare Billing
$100,465
Payment Breakdown by Category
Consulting$187,999 (69.9%)
Other$40,402 (15.0%)
Travel$15,148 (5.6%)
Research$14,110 (5.2%)
Education$6,913 (2.6%)
Food & Beverage$4,446 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $187,999 | 107 | 69.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,802 | 34 | 13.7% |
| Travel and Lodging | $15,148 | 43 | 5.6% |
| Unspecified | $14,110 | 16 | 5.2% |
| Education | $6,913 | 3 | 2.6% |
| Food and Beverage | $4,446 | 79 | 1.7% |
| Honoraria | $3,600 | 3 | 1.3% |
Payments by Type
General
$254,907
269 transactions
Research
$14,110
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62,841 | 59 | $0 (2023) |
| PFIZER INC. | $61,709 | 76 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $53,647 | 52 | $0 (2024) |
| F. Hoffmann-La Roche AG | $26,242 | 34 | $0 (2024) |
| Alkermes, Inc. | $11,348 | 5 | $0 (2020) |
| Exelixis Inc. | $9,502 | 10 | $0 (2024) |
| Eli Lilly and Company | $7,365 | 9 | $0 (2019) |
| Eisai Inc. | $6,225 | 4 | $0 (2024) |
| GENZYME CORPORATION | $5,844 | 1 | $0 (2022) |
| Genentech USA, Inc. | $4,784 | 8 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,206 | 12 | PFIZER INC. ($4,627) |
| 2023 | $14,613 | 24 | PFIZER INC. ($6,621) |
| 2022 | $24,389 | 32 | GENZYME CORPORATION ($5,844) |
| 2021 | $17,752 | 15 | E.R. Squibb & Sons, L.L.C. ($8,094) |
| 2020 | $39,773 | 32 | PFIZER INC. ($17,600) |
| 2019 | $61,053 | 61 | Merck Sharp & Dohme Corporation ($12,119) |
| 2018 | $54,034 | 67 | PFIZER INTERNATIONAL LLC ($16,397) |
| 2017 | $50,198 | 42 | Merck Sharp & Dohme Corporation ($21,619) |
All Payment Transactions
285 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/01/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| 09/30/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 09/13/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $62.07 | General |
| 08/22/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 07/22/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $446.72 | Research |
| Study: Association of machine learning (ML) derived histological features with transcriptomics based molecular subtypes in advanced renal cell carcinoma (RCC) • Category: BioOncology | ||||||
| 04/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $20.12 | General |
| Category: Oncology | ||||||
| 04/02/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 03/27/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,975.00 | General |
| Category: Oncology | ||||||
| 02/29/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 01/30/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $265.00 | General |
| 01/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $136.78 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/29/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| 12/22/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/18/2023 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| 11/28/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 11/13/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 11/02/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 10/22/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $66.41 | General |
| 10/22/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $62.67 | General |
| 10/21/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $69.29 | General |
| 10/19/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $135.00 | General |
| 09/14/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $660.00 | General |
| 08/23/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $40.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AXITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,070 | 5 |
| A Phase II, Randomized Study of Atezolizumab Anti-PD-L1 Antibody Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma, A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF Atezolizumab Anti PD-L1 ANTIBODY IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA IMmotion151 | F. Hoffmann-La Roche AG | $2,342 | 1 |
| A Phase II, Randomized Study of Atezolizumab Anti-PD-L1 Antibody Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | F. Hoffmann-La Roche AG | $756.70 | 1 |
| IMmotion 151 aPDL1 in Renal Cell Carcinoma RCC | F. Hoffmann-La Roche AG | $685.94 | 1 |
| WO29637 | F. Hoffmann-La Roche AG | $497.18 | 2 |
| Association of machine learning (ML) derived histological features with transcriptomics based molecular subtypes in advanced renal cell carcinoma (RCC) | F. Hoffmann-La Roche AG | $446.72 | 1 |
| A Phase II, Multicentre, Single-Arm Study of Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer, A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY IMvigor211, A Phase II, Randomized Study of Atezolizumab Anti-PD-L1 Antibody | F. Hoffmann-La Roche AG | $161.59 | 1 |
| GO29293, GO29294 | F. Hoffmann-La Roche AG | $64.95 | 1 |
| WO29074 | F. Hoffmann-La Roche AG | $58.04 | 1 |
| A Phase II, Multicentre, Single-Arm Study of Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer, A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY IMvigor211 | F. Hoffmann-La Roche AG | $14.38 | 1 |
| Bladder Cancer and Bladder Cancer | F. Hoffmann-La Roche AG | $12.95 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 111 | 223 | $71,546 | $17,142 |
| 2022 | 5 | 152 | 298 | $88,204 | $21,847 |
| 2021 | 4 | 141 | 404 | $124,004 | $32,658 |
| 2020 | 4 | 148 | 409 | $80,057 | $28,819 |
Total Patients
552
Total Services
1,334
Medicare Billing
$100,465
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 61 | 160 | $52,160 | $12,142 | 23.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 23 | 23 | $10,258 | $2,596 | 25.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 24 | $5,592 | $1,608 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 16 | $3,536 | $795.93 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 64 | 157 | $50,358 | $12,053 | 23.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 49 | $16,415 | $4,122 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 43 | 48 | $10,366 | $2,650 | 25.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 33 | $7,689 | $1,767 | 23.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 11 | 11 | $3,376 | $1,256 | 37.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 93 | 320 | $100,442 | $26,084 | 26.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 47 | $15,745 | $4,256 | 27.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 15 | 16 | $4,268 | $1,183 | 27.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 17 | 21 | $3,549 | $1,135 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 94 | 278 | $40,500 | $18,014 | 44.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 95 | $32,585 | $8,601 | 26.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 12 | 12 | $4,260 | $1,124 | 26.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 20 | 24 | $2,712 | $1,080 | 39.8% |
About Dr. David Mcdermott, MD
Dr. David Mcdermott, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033133251.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Mcdermott, MD has received a total of $269,017 in payments from pharmaceutical and medical device companies, with $7,206 received in 2024. These payments were reported across 285 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($187,999).
As a Medicare-enrolled provider, Mcdermott has provided services to 552 Medicare beneficiaries, totaling 1,334 services with total Medicare billing of $100,465. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 07/27/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1033133251
Products in Payments
- TECENTRIQ (Biological) $26,402
- OPDIVO (Biological) $22,589
- INLYTA (Drug) $18,563
- Lenvima (Drug) $6,225
- Tecentriq (Biological) $4,420
- Cabometyx (Drug) $4,321
- CABOMETYX (Drug) $4,097
- Bavencio (Biological) $4,004
- Avastin (Biological) $3,012
- Proleukin (Drug) $2,703
- WELIREG (Drug) $2,500
- FOTIVDA (Drug) $1,400
- KEYTRUDA (Biological) $1,057
- PROLEUKIN (Drug) $157.40
- VOTRIENT (Drug) $22.77
- OPDUALAG (Drug) $20.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795